144 related articles for article (PubMed ID: 33142043)
1. Postchemotherapy erythroid cannibalism in relapsed NPM1, FLT3-mutated acute myeloid leukemia.
Chauhan R; Kotwal J
Int J Lab Hematol; 2021 Apr; 43(2):e80-e81. PubMed ID: 33142043
[No Abstract] [Full Text] [Related]
2. Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Sid S; Rey J; Charbonnier A; D'Incan E; Mohty B; Blaise D; Vey N
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):241-242. PubMed ID: 28196687
[No Abstract] [Full Text] [Related]
3. "Cup-like" blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML).
Jain P; Vega-Vazquez F; Faderl S
Int J Hematol; 2013 Jul; 98(1):3. PubMed ID: 23690292
[No Abstract] [Full Text] [Related]
4. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Guenounou S; Delabesse E; Récher C
Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
[TBL] [Abstract][Full Text] [Related]
5. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
[TBL] [Abstract][Full Text] [Related]
6. Bone Marrow Clonogenic Myeloid Progenitors from
Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M; Bacher U; Ayuk F; Lebeau A
J Clin Pathol; 2010 Jun; 63(6):558-61. PubMed ID: 20360144
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
9. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
[TBL] [Abstract][Full Text] [Related]
10. "Cup-like" blasts in acute myeloid leukemia with FLT3 and NPM1 mutations.
Vidholia A; Menon MP
Blood; 2015 Jan; 125(5):889. PubMed ID: 25793242
[No Abstract] [Full Text] [Related]
11. FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
Loschi M; Sammut R; Chiche E; Cluzeau T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070902
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients.
Kassem NM; Medhat N; Kassem HA; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2421-2427. PubMed ID: 31450916
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
15. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
16. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
17. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
18. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
19. Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
Jo SY; Park SH; Kim IS; Yi J; Kim HH; Chang CL; Lee EY; Cho YU; Jang S; Park CJ; Chi HS
Ann Lab Med; 2016 Sep; 36(5):399-404. PubMed ID: 27374703
[TBL] [Abstract][Full Text] [Related]
20. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia.
Radojkovic M; Tosic N; Colovic N; Ristic S; Pavlovic S; Colovic M
Ann Clin Lab Sci; 2012; 42(2):186-90. PubMed ID: 22585616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]